^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DYP688
i
Other names: DYP688, DYP-688
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis
Drug class:
GNAQ inhibitor, GNA11 antagonist, gp100-targeted antibody-drug conjugate
Related drugs:
7ms
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
GNAQ (G Protein Subunit Alpha Q)
|
DYP688
2years
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
Trial completion date • Trial primary completion date • Metastases
|
GNAQ (G Protein Subunit Alpha Q)
|
DYP688
over2years
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the body (clinicaltrialsregister.eu)
P1/2, N=124, Novartis Pharma AG
New P1/2 trial
|
GNAQ (G Protein Subunit Alpha Q)
|
DYP688
over2years
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
P1/2, N=124, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
GNAQ (G Protein Subunit Alpha Q)
|
DYP688
over2years
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (clinicaltrials.gov)
P1/2, N=124, Not yet recruiting, Novartis Pharmaceuticals
New P1/2 trial
|
GNAQ (G Protein Subunit Alpha Q)
|
DYP688
Share via
